3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
11
Carcinoma, Non-Small-Cell Lung
3
Colonic Neoplasms
2
Thoracic Diseases
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Endobronchial Metastases
1
Disease Progression
1
Breast Neoplasms
1
Brain Neoplasms
1
Agnosia
1
Interventions
Docetaxel
19
pembrolizumab
14
Surveys and Questionnaires
7
Radiotherapy
7
Paclitaxel
7
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Standard of Care
6
Specimen Handling
6
Radiosurgery
6
Psychiatric Rehabilitation
6
Early Intervention, Educational
6
Trastuzumab
5
Nivolumab
5
enzalutamide
4
Interviews as Topic
4
motexafin gadolinium
3
cabozantinib
3
X-Rays
3
Sirolimus
3
Methods
3
Educational Status
3
Cisplatin
3
Carboplatin
3
Azacitidine
3
tisotumab vedotin
2
rucaparib
2
pertuzumab
2
pegilodecakin
2
palbociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Propofol
×
Thoracic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled